title: [Alprazolam use improves psychological status and reduces hospitalization costs in patients with paroxysmal supraventricular tachycardia underwent radiofrequency catheter ablation].
abstract: OBJECTIVE
  To evaluate the effect of alprazolam use on psychological status and hospitalization cost in patient with paroxysmal supraventricular tachycardia underwent electrophysiology studies or radiofrequency catheter ablation.
  
  
  METHODS
  In this prospective, randomized, double-blind, placebo-controlled study, 142 inpatients [77 males, mean age (43.1 +/- 14.5) years] were randomly assigned to receive alprazolam (0.4 mg qd at 10PM for 3 days, n = 72) or placebo (n = 70) 3 days before scheduled electrophysiology studies or radiofrequency catheter ablation. All patients were examined by the Chinese version of Symptom Checklist-90 (SCL-90) at 24 hours before the procedure.
  
  
  RESULTS
  Compared with the placebo group, the scores of somatization (1.38 +/- 0.40 vs. 1.65 +/- 0.56, P < 0.01), anxiety (1.50 +/- 0.39 vs. 1.69 +/- 0.50, P < 0.05), phobic anxiety (1.24 +/- 0.36 vs. 1.47 +/- 0.57, P < 0.01), psychotism constructs (1.24 +/- 0.34 vs. 1.35 +/- 0.30, P < 0.05) and global severity index (1.36 +/- 0.35 vs. 1.49 +/- 0.37, P < 0.05) were significantly decreased in alprazolam group. The hospitalization costs were also significantly lower in alprazolam group (32 498 +/- 1170) yuan compared to placebo group (32 947 +/- 1096) yuan, P < 0.05.
  
  
  CONCLUSIONS
  The alprazolam use before electrophysiology studies and radiofrequency catheter ablation can improve the patients' psychological status and reduce the hospitalization costs.
authors.affiliation: Department of Cardiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
authors.forename: Yu-juan
authors.initials: YJ
authors.lastname: Zhu
authors.forename: Zi-yan
authors.initials: ZY
authors.lastname: Liu
authors.forename: Yao
authors.initials: Y
authors.lastname: Chen
authors.forename: Ping
authors.initials: P
authors.lastname: Zheng
authors.forename: Jian-hua
authors.initials: JH
authors.lastname: Zhu
authors.forename: Qian-min
authors.initials: QM
authors.lastname: Tao
authors.forename: Liang-rong
authors.initials: LR
authors.lastname: Zheng
authors.forename: Qi-qi
authors.initials: QQ
authors.lastname: Wang
authors.forename: Ming-juan
authors.initials: MJ
authors.lastname: Shi
authors.forename: Yuan-gang
authors.initials: YG
authors.lastname: Qiu
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000525:Alprazolam / Q000627:therapeutic use*; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D017115:Catheter Ablation / Q000191:economics / Q000523:psychology*; D004311:Double-Blind Method; D005260:Female; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013614:Tachycardia, Paroxysmal / Q000523:psychology* / Q000628:therapy; D013617:Tachycardia, Supraventricular / Q000523:psychology* / Q000628:therapy; D055815:Young Adult
chemical_list: D014151:Anti-Anxiety Agents; D000525:Alprazolam